Skip to content

Medical emergency? What to do

Investigational study of ustekinumab in the treatment of psoriatic arthritis published

3-RXPublished February 12, 20094 min read

Key points

  • A group of patients suffering from potentially debilitating psoriatic arthritis showed significant and prolonged improvement after treatment with ustekinumab, according to data from a randomized, double-blind, placebo-controlled study in patients with moderate to severe psoriatic arthritis (PsA).
  • Ustekinumab is a human immunoglobulin monoclonal antibody that is also being studied for treatment of patients with moderate-to-severe plaque psoriasis.
  • Psoriatic arthritis is a chronic inflammatory arthropathy manifesting with joint pain and swelling that can lead to joint destruction and debilitation.
  • Tufts Medical Center was among several academic medical centers which participated in the study.

A group of patients suffering from potentially debilitating psoriatic arthritis showed significant and prolonged improvement after treatment with ustekinumab, according to data from a randomized, double-blind, placebo-controlled study in patients with moderate to severe psoriatic arthritis (PsA). The Phase 2 study was published in the British medical journal The Lancet.

"This is a positive development for patients living with the joint pain and swelling that characterizes the disease, even as more research is needed to further test the efficacy of this treatment in psoriatic arthritis," said Alice Gottlieb, MD, Chairperson of the Department of Dermatology at Tufts Medical Center and lead author of the study.

Tufts Medical Center was among several academic medical centers which participated in the study. Tufts Medical Center is a 451-bed hospital in Boston and the primary teaching hospital for Tufts University School of Medicine.

Ustekinumab is a human immunoglobulin monoclonal antibody that is also being studied for treatment of patients with moderate-to-severe plaque psoriasis. Researchers conducting the study published in The Lancet reported that at week 12 of the study, 42 percent of patients given 63 or 90 mg of the drug at weeks 0, 1, 2 and 3 showed significant improvement in their pain, stiffness and other symptoms defined by the American College of Rheumatology (ACR20) score compared with 14 percent of patients who received placebo at the same time points (P < 0.001). At week 36, 33 weeks after their last dose, approximately three quarters of patients who had achieved ACR 20 sustained the improvement in their psoriatic arthritis symptoms. Also at week 24, 12 weeks after their initial ustekinumab dose, 51 percent of patients who had initially received placebo at Weeks 0, 1, 2 and 3 achieved ACR 20 following two doses of ustekinumab at weeks 12 and 16.

A secondary endpoint of the study showed that of patients who had plaque psoriasis on at least 3 percent of their body, 52 percent receiving 63 or 90 mg ustekinumab at weeks 0, 1, 2 and 3 achieved at least a 75 percent improvement in psoriasis from baseline as measured by the Psoriasis Area and Severity Index (PASI 75) at week 12 compared with five percent of patients receiving placebo (P < 0.001).

Through week 12, the placebo-controlled portion of the study, the proportion of patients with at least one adverse event (AE) was similar between patients in Group 1 receiving ustekinumab (61 percent) and those in Group 2 receiving placebo (63 percent). There were no serious AEs in Group 1 versus 4 percent of patients (n=3) in Group 2. There were no deaths, no reports of malignancy, tuberculosis or serious infections in either group. Through week 36, after the placebo crossover, the pattern of AEs was similar to that observed through week 12 of the trial.

###

About Psoriatic Arthritis and Psoriasis

Psoriatic arthritis is a chronic inflammatory arthropathy manifesting with joint pain and swelling that can lead to joint destruction and debilitation. It is frequently associated with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include stiffness and tenderness of the joints and surrounding tissue and reduced range of motion. Joints of the hands, wrists, knees, ankles, feet, lower back and neck are commonly affected. Psoriasis affects an estimated two to three percent of the world's population, and approximately one out of three patients affected by psoriasis may develop psoriatic arthritis. Both men and women are equally affected by psoriatic arthritis, most commonly between the ages 30 and 50, in the peak of their productive years. Psoriasis affects two to four percent of the U.S. population. About a quarter of those with psoriasis have moderate to severe symptoms, and a third of those develop psoriatic arthritis.

Contact: Julie Jette
617-636-3265
Tufts University, Health Sciences

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Keep reading

Arthritis

Keeping Active With Diabetes and Arthritis

Daily physical activity is essential for good health and blood glucose control in people with diabetes. But what if you also have arthritis? One in five American adults has been diagnosed with arthritis, and half of…

16 min read

Arthritis

Obesity, Inactivity Increase Risk of Fibromyalgia

Researchers from the Norwegian University of Science and Technology have found a link between obesity in women and fibromyalgia, an incurable disease that causes chronic pain. The study found an increased risk for…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.